OakChart

Orchestra BioMed Holdings Inc

OBIOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.01+0.28 (4.89%)
2026-11-12 06:01 CET
Market cap
361.23 USD m
Revenue, TTM
31.21 USD m
Net income, TTM
-58.36 USD m
Free cash flow, TTM
-64.18 USD m
EPS diluted, TTM
-0.91
P/E
-
Compare

Price

OBIO against its 20, 50 and 200-day averages
2050200beatmiss
4.005.006.002.7M5.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OBIOclose 6.0120-day 5.7450-day 5.79200-day 4.606.0152w high52w low

7.5% under the 52-week high of 6.50 on 1 Oct 2026. 52-week low 3.46 on 30 Jan 2026. Last 15 sessions, 24.3% high to low

Volume 1.18× normal · the line is the 50-bar volume average

Profile

OBIO
52-week range, 84% of the way up
3.466.50

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

IndexRUT
Employees86
IPOAug 04, 2020
Beta0.56
ATR, 14d0.41
Rel volume1.18
Short float6.60%
Insider own31.12%
Inst own46.59%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap361.23M
Enterprise Value343.82M
Income-58.36M
Sales31.21M
Book/sh0.13
Cash/sh1.70
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees86
IPOAug 04, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S11.57
P/B47.46
P/C3.54
P/FCF-
EV/EBITDA-
EV/Sales11.02
Quick Ratio7.24
Current Ratio7.25
Debt/Eq3.92
LT Debt/Eq3.88
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.91
EPS next Y-1.45
EPS next Q-0.38
EPS this Y-30.56%
EPS next Y-0.27%
EPS next 5Y4.44%
EPS past 3/5Y20.91% -164.92%
Sales past 3/5Y111.62% -
EPS Y/Y TTM50.23%
Sales Y/Y TTM1007.38%
EPS Q/Q23.93%
Sales Q/Q-89.43%
EarningsNov 10 AMC
EPS/Sales Surpr.25.13% -29.68%

Ownership

Insider Own31.12%
Insider Trans0.12%
Inst Own46.59%
Inst Trans6.98%
ROA-53.59%
ROE-182.29%
ROIC-62.27%
Gross Margin98.61%
Oper. Margin-195.39%
Profit Margin-187.02%
SMA204.67%
SMA503.80%
SMA20030.65%
Trades-

Technical

Shs Outstand61.45M
Shs Float41.40M
Short Float6.60%
Short Ratio7.14
Short Interest2.73M
52W High6.50 -7.54%
52W Low3.46 73.70%
Volatility10.04% 6.90%
ATR (14)0.41
RSI (14)55.59
Beta0.56
Rel Volume1.18
Avg Volume382.49K
Volume452,905

Performance

Perf Week0.17%
Perf Month5.07%
Perf Quarter35.06%
Perf Half Y48.03%
Perf YTD44.82%
Perf Year46.59%
Perf 3Y14.04%
Perf 5Y-39.05%
Perf 10Y-
Recom1.00
Target Price12.43
Prev Close5.73
Price6.01
Change %4.89%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 10, 2026UpgradeBBTIG ResearchNeutral → Buy$10+66.4%
Dec 10, 2025InitiatedTTD CowenBuy$15+149.6%
Aug 20, 2025DowngradeBBTIG ResearchBuy → Neutral
Mar 20, 2025InitiatedBBTIG ResearchBuy$12+99.7%
Jan 02, 2025InitiatedBBarclaysOverweight$16+166.2%
Aug 22, 2024InitiatedHH.C. WainwrightBuy$14+132.9%
Jul 25, 2024InitiatedRB. Riley SecuritiesBuy$15+149.6%
Jan 19, 2024InitiatedJJefferiesBuy$14+132.9%
Feb 24, 2023InitiatedPPiper SandlerOverweight$15+149.6%
Feb 07, 2023InitiatedCChardan Capital MarketsBuy$20+232.8%

Peers

Mkt cap
TickerCompanyMkt cap
CVRXCVRx Inc19.95M
MLYSMineralys Therapeutics Inc1.43B
BSXBoston Scientific Corp65.41B
MDTMedtronic Plc129.98B
INSPInspire Medical Systems Inc1.80B
ATRCAtricure Inc2.93B
STXSStereotaxis Inc90.18M
LMATLemaitre Vascular Inc1.81B
PLSEPulse Biosciences Inc4.19B
ECORElectroCore Inc71.13M

Insider trading

latest 14 of 25
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Fain Eric SDirectorNov 09 '26Buy5.0020,000100,000119,630Nov 09 04:32 PM
Pacitti DavidDirectorNov 09 '26Buy5.0020,000100,00074,750Nov 09 04:31 PM
Hochman David PSee RemarksNov 09 '26Buy5.005,00025,000437,916Nov 09 04:31 PM
Taylor Andrew LawrenceChief Financial OfficerNov 09 '26Buy5.001,0005,000590,989Nov 09 04:30 PM
Sherman DarrenSee RemarksNov 02 '26Sale5.7415,00086,1001,104,402Nov 03 05:14 PM
Sherman DarrenOfficerNov 02 '26Proposed Sale5.9215,00088,800Nov 02 11:51 AM
Sherman DarrenSee RemarksOct 01 '26Sale6.3615,00095,4001,119,402Oct 02 04:30 PM
Sherman DarrenOfficerOct 01 '26Proposed Sale6.2715,00094,050Oct 01 10:37 AM
Hochman David PSee RemarksSep 03 '26Buy4.7910,00047,9001,070,746Sep 08 08:15 AM
Sherman DarrenSee RemarksSep 01 '26Sale4.9415,00074,1001,134,402Sep 02 04:15 PM
Sherman DarrenOfficerSep 01 '26Proposed Sale5.0215,00075,300Sep 01 11:59 AM
Sherman DarrenSee RemarksAug 26 '26Buy5.332,00010,6602,000Aug 28 04:15 PM
Sherman DarrenSee RemarksAug 03 '26Sale4.0915,00061,3501,154,327Aug 04 04:49 PM
Sherman DarrenOfficerAug 03 '26Proposed Sale4.0915,00061,292Aug 03 04:34 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SURISimplify Propel Opportunities ETFAUM: 74.30M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B

News

latest 14 of 198
  • Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
  • Orchestra BioMed Announces Pricing of Public Offering (GlobeNewswire) -6.33%
  • Orchestra BioMed Announces Proposed Public Offering (GlobeNewswire)
  • Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026 (GlobeNewswire)
  • Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue SAB (GlobeNewswire) -5.77%
  • OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports (Investing.com)
  • Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy (GlobeNewswire)
  • Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 (GlobeNewswire)
  • Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics (GlobeNewswire)
  • Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
  • Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates (GlobeNewswire) +5.19%
  • Orchestra BioMed Joins Russell 3000 and Russell 2000 Indexes (GlobeNewswire) +12.03%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.300-0.401-0.3040.090.137
2026Q22026-08-10-0.380-0.392-0.3770.090.147
2026Q12026-05-12-0.330-0.431-0.3290.110.928
2025Q42026-03-120.118-0.3780.10530.920.938
2025Q32025-11-10-0.400-0.397-0.3990.860.745
2025Q22025-08-12-0.500-0.500-0.5040.840.786
2025Q12025-05-12-0.490-0.480-0.4910.870.527
2024Q42025-03-31-0.420-0.426-0.4250.250.847
2024Q32024-11-12-0.410-0.430-0.4100.990.704
2024Q22024-08-12-0.450-0.393-0.4460.780.854
2024Q12024-05-13-0.380-0.397-0.3760.620.953
2023Q42024-03-27-0.350-0.377-0.3580.260.992
2023Q32023-11-13-0.380-0.390-0.3780.420.902
2023Q22023-08-10-0.350-0.415-0.3480.920.712
2023Q12023-05-12-0.400-0.285-0.3961.160.682
2022Q42023-03-07-1.710-3.140-0.0781.181.181

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-14.600-13.860-2.2423.214.31
2023FY-1.480-1.483-1.4782.763.53
2024FY-1.660-1.658-1.6572.643.21
2025FY-1.110-1.742-1.11033.483.47
2026FY--1.449--0.45
2027FY--1.453--0.58
2028FY--0.969--13.88
2029FY--0.400--49.42
2030FY-0.275--102.32

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-117120.130.090.30
2026Q4S2026-11-107120.130.090.30
2026Q4S2026-11-037120.130.090.30
2026Q4S2026-10-287210.140.090.30
2026Q4S2026-10-267120.130.090.30
2026Q4S2026-10-257210.140.090.30
2026Q4S2026-10-227310.140.090.30
2026Q4S2026-10-127220.130.090.30
2026Q4S2026-10-097310.140.090.30
2026Q4S2026-10-017220.130.090.30
2026Q4S2026-09-147130.130.090.30
2026Q4S2026-09-097130.130.090.30
2026Q4S2026-08-117120.140.090.30
2026Q4S2026-07-297010.140.100.26

Estimate history

EPS, annual-0.009-0.019-2.242-1.478-1.657-1.109-0.9052
Period202020212022202320242025TTM
EPS, quarterly-0.41-0.425-0.491-0.504-0.3990.105-0.329-0.377-0.304
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual003.5332.762.63833.48231.21
Period202020212022202320242025TTM
Sales, quarterly0.9870.2530.8680.8360.86130.9170.110.0880.091
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.4520.4520.18835.77738.19457.03361.453
Period202020212022202320242025MRQ
Shares, quarterly37.94338.19438.31338.64456.46557.03358.63160.10561.453
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue31.2133.482.642.763.530.000.00
Cost of Goods Sold Incl. D&A0.430.350.360.330.320.000.00
Gross Profit30.7733.132.282.433.210.000.00
Selling, General and Administrative Excl. Other91.7884.9466.5853.9435.870.390.18
Research and Development66.9358.1942.8033.8221.95--
Other Operating Expense-0.030.000.000.000.000.000.00
Operating Income-60.97-51.81-64.30-51.51-32.66-0.39-0.18
Interest Expense5.821.15--0.000.000.00
Unusual Expense-1.41-0.250.071.461.000.000.00
Net Income Before Taxes-56.95-52.70-61.02-49.12-33.61-0.38-0.17
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-56.95-52.70-61.02-49.12-33.61-0.38-0.17
Net Income From Continuing Operations-56.95-52.70-61.02-49.12-33.61-0.38-0.17
Net Income-58.36-52.95-61.02-49.12-33.61-0.38-0.17
EPS (Recurring)-0.92-1.11-1.66-1.45-2.20-0.02-0.01
EPS (Basic, Before Extraordinaries)-0.91-1.11-1.66-1.48-2.24-0.02-0.01
EPS (Diluted)-0.91-1.11-1.66-1.48-2.24-0.02-0.01
EBITDA-60.60-51.48-63.99-51.22-32.44-0.39-0.18
Non-Operating Income (Expense)8.430.003.353.850.050.020.01
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense10.3911.9810.627.623.38--
Price To Sales Ratio12.885.9255.83109.9142.34--
Gross Margin98.6198.9486.4388.0690.89--
Operating Margin-195.39-154.73-2,437.49-1,866.16-924.34--
Net Margin-187.02-158.16-2,313.27-1,779.71-951.26--
Shares Outstanding61.4557.0338.1935.7820.1920.4520.45
Market Capitalization361.23361.23152.05326.34111.90206.14261.96

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.090.090.1130.920.860.840.870.25
Cost of Goods Sold Incl. D&A0.130.120.090.090.130.130.130.10
Gross Profit-0.04-0.030.0230.820.730.710.740.15
Selling, General and Administrative Excl. Other23.2622.3222.1224.0721.0420.0419.6616.83
Research and Development17.7316.5915.7816.8214.0313.8513.4810.97
Other Operating Expense0.000.00-0.030.000.000.000.000.00
Operating Income-23.30-22.36-22.086.75-20.31-19.33-18.92-16.68
Interest Expense2.461.770.820.760.52---
Unusual Expense-0.87-0.320.04-0.250.000.000.000.00
Net Income Before Taxes-18.75-23.75-20.696.25-20.83-19.36-18.75-16.16
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.75-23.75-20.696.25-20.83-19.36-18.75-16.16
Net Income From Continuing Operations-18.75-23.75-20.696.25-20.83-19.36-18.75-16.16
Net Income-19.62-24.08-20.665.99-20.83-19.36-18.75-16.16
EPS (Recurring)-0.31-0.38-0.330.10-0.40-0.50-0.49-0.42
EPS (Basic, Before Extraordinaries)-0.30-0.38-0.330.10-0.40-0.50-0.49-0.42
EPS (Diluted)-0.30-0.38-0.330.10-0.40-0.50-0.49-0.42
EBITDA-23.20-22.26-21.996.84-20.23-19.25-18.84-16.59
Non-Operating Income (Expense)6.140.042.240.000.000.000.170.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.292.502.852.753.013.252.962.90
Price To Sales Ratio12.888.618.157.0745.9334.9556.7057.65
Gross Margin-41.76-37.5016.3699.7084.9084.8185.3760.47
Operating Margin-25,600.00-25,404.55-20,069.0921.85-2,359.23-2,311.84-2,179.84-6,591.70
Net Margin-21,557.14-27,362.50-18,778.1819.38-2,419.05-2,316.15-2,160.71-6,385.38
Shares Outstanding61.4560.1158.6357.0356.4638.6438.3138.19
Market Capitalization361.23258.39248.71234.33133.81102.68162.70152.05

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments106.5166.8187.5983.781.752.03
Short Term Receivables0.100.090.100.100.000.00
Inventories0.310.170.150.280.000.00
Other Current Assets0.992.091.270.530.050.12
Total Current Assets107.9169.1789.1184.691.802.15
Net Property, Plant & Equipment3.213.492.833.680.000.00
Total Investments and Advances2.502.502.502.50160.02160.01
Intangible Assets---0.000.000.00
Other Assets1.241.020.774.710.000.00
Total Assets114.8676.1795.2195.57161.82162.16
Short Term Debt Incl. Current Port. of LT Debt0.750.550.650.700.000.00
Accounts Payable6.095.132.903.970.000.00
Other Current Liabilities9.8910.527.6613.900.170.12
Total Current Liabilities16.7416.2111.2118.570.170.12
Long Term Debt31.6915.981.0411.170.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities3.0611.0314.9213.305.605.60
Total Liabilities51.4843.2227.1743.045.775.72
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value9.810.000.000.000.000.00
Common Equity53.5732.9668.0452.53156.06156.44
Total Shareholders Equity63.3832.9668.0452.53156.06156.44
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity63.3832.9668.0452.53156.06156.44
Total Liabilities & Stockholders Equity114.8676.1795.2195.57161.82162.16
Book Value Per Share0.940.861.902.607.637.65
Tangible Book Value Per Share0.940.861.902.607.637.65
Full-Time Employees867056444
Price to Book Ratio47.463.284.101.821.321.67
Return on Assets-55.18-71.21-60.16-26.11-0.23-
Return on Equity-109.41-120.84-76.29-32.22-0.24-
Return on Invested Capital-55.44-124.70-71.10-52.75-0.24-0.11
Quick Ratio6.434.267.944.5510.8818.07
Current Ratio6.454.277.954.5610.8818.07

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-56.95-52.70-61.02-49.12-33.61-0.38-0.17
Depreciation0.370.330.310.290.22--
Other Funds (Non Cash)8.4713.7810.926.014.55-0.02-0.01
Funds from Operations-48.11-38.59-49.79-42.82-28.84-0.39-0.18
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-15.20-10.37-0.77-3.31-0.450.12-0.08
Cash from Operating Activities-63.31-48.96-50.56-46.13-29.29-0.27-0.26
Capital Expenditures-0.87-0.49-0.29-0.08-0.590.000.00
Net Assets From Acquisitions0.000.00-0.600.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-8.87-26.4513.9810.77-63.530.00-160.00
Purchase of Investments-88.25-76.31-72.65-142.03-63.530.00-160.00
Sale Or Maturity of Investments79.3849.8686.63152.800.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-9.74-26.9413.0910.69-64.120.00-160.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock26.0171.9715.280.250.190.00162.29
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock26.0171.9715.280.250.190.00162.29
Proceedsfrom Stock Options13.411.5415.040.000.000.00162.29
Issuance or Reduction of Debt, Net34.0317.9115.00-10.853.550.000.00
Change in Long Term Debt34.0317.9115.00-10.853.550.000.00
Issuance of Long Term Debt35.0018.8915.000.0010.000.000.00
Reduction of Long Term Debt-0.97-0.970.00-10.85-6.450.000.00
Net Financing Active Other Cash Flow-1.25-1.55-1.1056.8199.510.000.00
Other Financing Activities Uses-1.25-1.55-1.100.00-10.320.000.00
Cash from Financing Activities58.8088.3329.1746.22103.260.00162.29
Net Change in Cash-14.2512.43-8.3010.789.85-0.272.03
Free Cash Flow-64.18-49.45-50.85-46.20-29.88-0.27-0.26
Preferred Dividends (Cash Flow)--0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments101.91109.9694.40106.5195.8233.92
Short Term Receivables0.060.050.080.100.050.08
Inventories0.220.250.280.310.360.18
Other Current Assets0.990.981.450.991.531.69
Total Current Assets103.17111.2496.21107.9197.7735.88
Net Property, Plant & Equipment3.293.223.193.213.253.17
Total Investments and Advances0.000.000.002.502.502.50
Other Assets1.281.241.261.241.301.28
Total Assets107.74115.70100.66114.86104.8142.83
Short Term Debt Incl. Current Port. of LT Debt0.830.810.790.750.700.64
Accounts Payable5.036.136.316.098.475.31
Other Current Liabilities8.376.536.599.8911.4911.11
Total Current Liabilities14.2313.4713.6916.7420.6617.06
Long Term Debt72.7169.9532.8531.6931.5115.71
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.052.863.153.068.919.76
Total Liabilities88.9986.2849.6951.4861.0742.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value10.9610.109.779.810.000.00
Common Equity7.7819.3241.1953.5743.740.29
Total Shareholders Equity18.7529.4250.9763.3843.740.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.7529.4250.9763.3843.740.29
Total Liabilities & Stockholders Equity107.74115.70100.66114.86104.8142.83
Book Value Per Share0.130.320.700.940.770.01
Tangible Book Value Per Share0.130.320.700.940.770.01
Full-Time Employees---86--
Price to Book Ratio47.466.144.525.36325.036.09
Return on Assets-53.59-74.47-68.42-55.18-83.39-121.00
Return on Equity-182.29-397.30-161.12-109.41-166.97-313.82
Return on Invested Capital-20.50-23.91-24.696.57-27.68-120.97
Quick Ratio7.248.247.016.434.722.09
Current Ratio7.258.267.036.454.732.10

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.75-23.75-20.696.25-20.83-19.36
Depreciation0.100.100.090.080.080.08
Other Funds (Non Cash)-1.524.222.103.683.663.40
Funds from Operations-20.17-19.44-18.5010.01-17.09-15.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.640.11-3.66-12.282.540.36
Cash from Operating Activities-19.54-19.33-22.17-2.27-14.55-15.53
Capital Expenditures-0.40-0.25-0.18-0.03-0.31-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments21.36-23.0510.50-17.68-38.2716.39
Purchase of Investments-6.49-43.00-13.12-25.63-47.780.00
Sale Or Maturity of Investments27.8619.9523.637.959.5116.39
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities20.96-23.3110.32-17.71-38.5816.36
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)----0.000.00
Change in Capital Stock6.020.015.8814.1057.780.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.020.015.8814.1057.780.00
Proceedsfrom Stock Options6.010.005.861.540.000.00
Issuance or Reduction of Debt, Net0.0035.000.00-0.9718.890.00
Change in Long Term Debt0.0035.000.00-0.9718.890.00
Issuance of Long Term Debt0.0035.000.000.0018.890.00
Reduction of Long Term Debt0.000.000.00-0.970.000.00
Net Financing Active Other Cash Flow-0.16-0.26-0.35-0.47-0.27-0.43
Other Financing Activities Uses-0.16-0.26-0.35-0.47-0.27-0.43
Cash from Financing Activities5.8634.755.5312.6676.40-0.43
Net Change in Cash7.29-7.89-6.32-7.3223.260.40
Free Cash Flow-19.94-19.59-22.35-2.30-14.86-15.56

Revenue breakdown

Partnership2024: 2.01M 2025: 32.87M
Product2024: 633.00K 2025: 611.00K
United States2024: 2.64M 2025: 33.48M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.60%2.7M41.4M334.24K
2026-10-156.17%2.6M41.4M298.61K
2026-09-306.15%2.5M41.4M295.65K
2026-09-155.73%2.4M41.4M366.84K
2026-08-315.95%2.5M41.4M342.54K
2026-08-145.76%2.4M41.4M316.72K
2026-07-315.88%2.4M41.3M326.92K
2026-07-156.27%2.6M41.3M330.82K
2026-06-305.39%2.2M41.3M307.06K
2026-06-153.00%1.2M41.3M217.22K
2026-05-292.30%0.9M41.2M221.15K
2026-05-152.03%0.8M41.6M212.03K
2026-04-302.41%1.0M40.3M201.15K
2026-04-152.03%0.9M43.8M198.86K
2026-03-312.19%1.0M43.8M218.50K
2026-03-131.82%0.8M43.8M207.68K
2026-02-271.89%0.8M42.2M201.78K
2026-02-131.80%0.8M42.2M233.13K
2026-01-301.90%0.8M43.4M252.34K
2026-01-151.82%0.8M43.4M276.78K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.704.103.507.8401.000.000.969-0.0130.001
call5.000.751.451.052.5052936.000.896-0.0100.002
call7.500.000.150.011.52238410.000.208-0.0230.003
call10.000.003.800.051.9891200.000.068-0.0140.001
put2.500.000.750.003.5570.000.00-0.031-0.0130.001
put5.000.000.050.051.6502397.00-0.156-0.0210.002
put7.500.104.900.0010.7540.000.00-0.792-0.0220.003
put10.003.404.800.004.7950.000.00-0.857-0.0300.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-098-KCurrent report2026-11-05SEC
2026-11-06424B5SEC
2026-11-05424B5SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11230.00K486.10K1
2026-100095.40K1
2026-0947.90K174.10K1
2026-0810.66K161.35K1
2026-070000
2026-0619.15K158.05K1
2026-05138.93K400
2026-04001321
2026-0342.90K100
2026-020000
2026-010000
2025-120000
2025-1120.35K100

Institutional holders

Manager% owned
RTW INVESTMENTS, LP15.96%
PERCEPTIVE ADVISORS LLC8.41%
BlackRock, Inc.4.19%
VANGUARD CAPITAL MANAGEMENT LLC3.38%
GEODE CAPITAL MANAGEMENT, LLC1.67%
Alyeska Investment Group, L.P.1.67%
Propel Bio Management, LLC1.50%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.07%
UBS Group AG0.87%
STATE STREET CORP0.86%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.45%
iShares Russell 2000 ETF1.39%
VANGUARD EXTENDED MARKET INDEX FUND0.83%
Fidelity Small Cap Index Fund0.72%
iShares Russell 2000 Growth ETF0.63%
VANGUARD RUSSELL 2000 INDEX FUND0.38%
Simplify Propel Opportunities ETF0.37%
BlackRock Health Sciences Opportunities Portfolio0.34%
Schwab U.S. Small-Cap ETF0.33%
Fidelity Extended Market Index Fund0.22%

OakChart. OBIO. Cached 15 minutes.